USD 303.32
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 44.08 Billion CHF | 2.8% |
2022 | 42.88 Billion CHF | -0.63% |
2021 | 43.15 Billion CHF | 2.39% |
2020 | 42.14 Billion CHF | -2.25% |
2019 | 43.11 Billion CHF | 8.94% |
2018 | 39.57 Billion CHF | 12.69% |
2017 | 35.12 Billion CHF | 2.1% |
2016 | 34.39 Billion CHF | 5.23% |
2015 | 32.68 Billion CHF | -4.1% |
2014 | 34.08 Billion CHF | -2.16% |
2013 | 34.83 Billion CHF | 4.53% |
2012 | 33.32 Billion CHF | 8.94% |
2011 | 30.58 Billion CHF | -10.51% |
2010 | 34.18 Billion CHF | -0.74% |
2009 | 34.43 Billion CHF | 7.76% |
2008 | 31.95 Billion CHF | -1.34% |
2007 | 32.39 Billion CHF | 3.07% |
2006 | 31.42 Billion CHF | 19.91% |
2005 | 26.2 Billion CHF | 8.78% |
2004 | 24.09 Billion CHF | 5.18% |
2003 | 22.9 Billion CHF | 7.57% |
2002 | 21.29 Billion CHF | 2.25% |
2001 | 20.82 Billion CHF | 6.74% |
2000 | 19.5 Billion CHF | 4.37% |
1999 | 18.69 Billion CHF | 11.53% |
1998 | 16.76 Billion CHF | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 11.64 Billion CHF | 0.0% |
2024 Q1 | 11.64 Billion CHF | -43.64% |
2023 FY | 44.08 Billion CHF | 2.8% |
2023 Q3 | 10.92 Billion CHF | -50.89% |
2023 Q4 | 20.65 Billion CHF | 89.11% |
2023 Q2 | 22.24 Billion CHF | 93.43% |
2023 Q1 | 11.49 Billion CHF | -47.49% |
2022 FY | 42.88 Billion CHF | -0.63% |
2022 Q4 | 21.89 Billion CHF | 88.61% |
2022 Q1 | 12.32 Billion CHF | -42.99% |
2022 Q2 | 22.54 Billion CHF | 82.88% |
2022 Q3 | 11.61 Billion CHF | -48.5% |
2021 Q1 | 11.53 Billion CHF | -43.97% |
2021 FY | 43.15 Billion CHF | 2.39% |
2021 Q3 | 11.7 Billion CHF | -45.47% |
2021 Q4 | 21.62 Billion CHF | 84.66% |
2021 Q2 | 21.47 Billion CHF | 86.15% |
2020 FY | 42.14 Billion CHF | -2.25% |
2020 Q1 | 11.32 Billion CHF | -48.32% |
2020 Q2 | 21.37 Billion CHF | 88.77% |
2020 Q3 | 10.91 Billion CHF | -48.92% |
2020 Q4 | 20.58 Billion CHF | 88.57% |
2019 Q4 | 21.91 Billion CHF | 89.97% |
2019 Q1 | 11.64 Billion CHF | 9.41% |
2019 Q2 | 11.64 Billion CHF | 0.0% |
2019 FY | 43.11 Billion CHF | 8.94% |
2019 Q3 | 11.53 Billion CHF | -1.0% |
2018 Q1 | 10.84 Billion CHF | 8.49% |
2018 FY | 39.57 Billion CHF | 12.69% |
2018 Q4 | 10.64 Billion CHF | 0.0% |
2018 Q3 | 10.64 Billion CHF | -1.78% |
2018 Q2 | 10.84 Billion CHF | 0.0% |
2017 Q2 | 9.93 Billion CHF | 0.0% |
2017 Q1 | 9.93 Billion CHF | 5.72% |
2017 FY | 35.12 Billion CHF | 2.1% |
2017 Q4 | 9.99 Billion CHF | 0.0% |
2017 Q3 | 9.99 Billion CHF | 0.57% |
2016 Q1 | 9.38 Billion CHF | 2.7% |
2016 FY | 34.39 Billion CHF | 5.23% |
2016 Q2 | 9.38 Billion CHF | 0.0% |
2016 Q4 | 9.39 Billion CHF | 0.0% |
2016 Q3 | 9.39 Billion CHF | 0.19% |
2015 FY | 32.68 Billion CHF | -4.1% |
2015 Q1 | 8.94 Billion CHF | -3.71% |
2015 Q4 | 9.13 Billion CHF | 0.0% |
2015 Q3 | 9.13 Billion CHF | 2.12% |
2015 Q2 | 8.94 Billion CHF | 0.0% |
2014 Q3 | 9.28 Billion CHF | 1.47% |
2014 FY | 34.08 Billion CHF | -2.16% |
2014 Q4 | 9.28 Billion CHF | 0.0% |
2014 Q2 | 9.15 Billion CHF | 0.0% |
2014 Q1 | 9.15 Billion CHF | 1.3% |
2013 FY | 34.83 Billion CHF | 4.53% |
2013 Q2 | 9.07 Billion CHF | 0.0% |
2013 Q3 | 9.03 Billion CHF | -0.47% |
2013 Q4 | 9.03 Billion CHF | 0.0% |
2013 Q1 | 9.07 Billion CHF | 0.0% |
2012 FY | 33.32 Billion CHF | 8.94% |
2011 FY | 30.58 Billion CHF | -10.51% |
2010 FY | 34.18 Billion CHF | -0.74% |
2009 FY | 34.43 Billion CHF | 7.76% |
2008 FY | 31.95 Billion CHF | -1.34% |
2007 FY | 32.39 Billion CHF | 3.07% |
2006 FY | 31.42 Billion CHF | 19.91% |
2005 FY | 26.2 Billion CHF | 8.78% |
2004 FY | 24.09 Billion CHF | 5.18% |
2003 FY | 22.9 Billion CHF | 7.57% |
2002 FY | 21.29 Billion CHF | 2.25% |
2001 FY | 20.82 Billion CHF | 6.74% |
2000 FY | 19.5 Billion CHF | 4.37% |
1999 FY | 18.69 Billion CHF | 11.53% |
1998 FY | 16.76 Billion CHF | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AstraZeneca PLC | 34.69 Billion USD | -27.068% |
Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | -28.476% |
CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -46.273% |
Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -392211.115% |
Novartis AG | 34.18 Billion USD | -28.946% |
PT Kalbe Farma Tbk. | 743.47 Million USD | -5829.468% |